Merck will collaborate with Syndax to evaluate the pairing of an anti-PD-1 therapy in Keytruda with HDAC inhibitor entinostat.
The focus will now include cardiovascular disease.
Pfizer spent over $1 billion on ads last year; Monday's M&A activity accounted for about 25% of this year's total; Actavis is selling its Australian generics business
The drugmaker known for its massive presence in generics purchased Auspex Pharmaceuticals to bolster its growing specialty business.
Horizon Pharma's purchase of Hyperion Therapeutics will add two rare-disease drugs to its portfolio.
The White House's National Action Plan for Reducing Antibiotic-Resistant Bacteria proposal includes $1.2 billion in funding to reduce superbug infections and develop new diagnostics.
Key contributors to the total: Sovaldi, Harvoni and Olysio
UnitedHealth Group buys PBM Catamaran; Sanofi launches Toujeo; Teva acquires Auspex Pharmaceuticals
Novo announces it will resubmit Tresiba to the FDA; WHO urges Europe to share cost-effectiveness data; J&J and Google partner to develop robotic surgery system
Diagnoses spiked in states with expanded Medicaid programs. This may mean higher prescription rates, but research shows a lack of diagnoses also has a price.
The duo hope to begin testing a new treatment within three years.
An editorial says the industry's use of terms like "low T" and "andropause" are false and misleading.
Regeneron's Eylea won its fourth indication; Sun Pharma wants to revive trust in its products; confidentiality agreements keep Amgen from telling patients their cancer risk
Panelists at a healthcare innovation conference said clinical research and local physician practices need to do more for women's health.
The drugmaker inks deal with Novo Nordisk to access its biologic discovery research platform.
Keytruda trial stopped due to positive results; new bill proposes continuing FDA rare pediatric voucher program; AstraZeneca signs five-year research pact with Harvard Stem Cell Institute
The proposal is part of the 21st Century Cures initiative and would permit drugmakers to provide information about "scientific and medical developments" when communicating with providers and payers.
An Alliance for Safe Biologic Medicines survey shows what doctors mean by biosimilar transparency.
Angelina Jolie Pitt discloses she had her fallopian tubes and ovaries removed; the FDA's Zyprexa investigation was inconclusive; Takeda and ImmunoGen sign a $20-million deal
The $38-million deal expands the reach of rare-disease campaigns.
Nielsen data shows pharma spent $4.5 billion on DTC ads last year.
A painkiller manufacturer said abuse-resistant formula lessens abuse, just as the FDA comes under pressure to finalize labeling guidance.
Mario Muredda and Mardene Miller will serve as co-presidents at the healthcare marketing agency.
A study shows that greater access to healthcare and lower smoking rates have not made baby boomers healthier than their parents.
Eleven new drugs with blockbuster potential are expected to launch this year; a bill would require FDA to quickly review drugs approved in the EU; Biogen reinforces its focus on hard-to-treat diseases
A judge rules against Amgen in Neupogen case; FDA advisory panel recommends Breio Ellipta for adults with asthma; AstraZeneca partners with Daiichi Sankyo to sell Movantik
An American Society of Clinical Oncology report shows the organization wants healthcare professionals to think in terms of value.
The Paris-based drugmaker's global president of R&D said that jumping through different and inconsistent regulatory hoops puts an "enormous" cost on drugmakers.
A group of computer science and engineering students at the Carlos III Universidad in Madrid used natural language processing techniques to translate social-media and forum posts into adverse drug reaction data.
A Florida Congressman introduced a bill that would expand patent protections; Novo Nordisk expects to increase diabetes medication prices; AbbVie expanded its Alzheimer's research
Oncology and diabetes medications are expected to be major areas of growth.
The diabetes device manufacturer will soon work with Glooko's platform.
The drugmaker, which markets the Dimetapp cough and cold line, sent a complaint to the Better Business Bureaus.
GlaxoSmithKline respiratory drug's safety profile will be evaluated by FDA advisory panel; Actavis axes 400 New York jobs; physician testifies that he falsified Diovan clinical trial data
The personal genetics company created a therapeutics group to extricate new drug targets from its research database.
Increased FDA scrutiny has not garnered trust for the new medications.
Interim results show cancer drug Imbruvica works well with other treatments; two studies show pricey new HCV medications are cost effective; the American College of Physicians wants less cardiac testing
Amgen and Sanofi/Regeneron shared clinical trial data that shows PCSK9 inhibitors dropped LDL levels by around 60%.
The approval follows three advisory panel reviews and a complete response letter.
New data suggest Amgen's PCSK9 may reduce risks of heart attacks, Salix bidding is war too rich for Endo's blood, Actavis bipolar drug use is expanded to 10- to 17-year-olds.
J&J sues GlaxoSmithKline over Flonase ads, CDC report finds patients with invasive cancer are living for five years or longer have diagnosis, and Bristol-Myers Squibb resubmits its HCV treatment.
Reactions to the first biosimilar approval show that marketing and education will be essential for the new category to take market share.
The research will be released as pharmacy benefit managers raise concerns about the potential costs of PCSK9 inhibitors.
The CMO of CVS Health said biosimilars could drive down prices 10% to 20% lower than current investor expectations.
The SEC said some company drug prices can be made public, 23andMe launched an R&D division, and Public Citizen is asking the FDA to withdraw a proposal it says will undermine drug safety information.
The company argues its offer for Salix is superior to the terms offered by serial acquirer Valeant.
The CMS said the issues should be resolved this week and will not affect this month's deadline for companies to submit payment data from 2014.
America's Health Insurance Plans offered its opinion of the Actavis Namenda IR antitrust case, giving its support to New York Attorney General Eric Schneiderman.
The partners will focus on developing treatments for metabolic disorders.
Zogenix spins off painkiller business; Biogen Idec investigates the use of wearables in MS patients; J&J sues Celltrion and Hospira to delay Remicade biosimilar.
PBM Express Scripts said last year's trends reflect a major shift in how the pharmaceutical industry does business and that generics are not the bargain they once were.
The agency's Office of Prescription Drug Promotion said a website indicated safety and effectiveness of a diagnostic tool that has not been approved by the FDA.
A recent analysis found that most websites touting personal cancer medicine failed to provide risk data, while an insurer and a health system team up to develop best practices to improve the "how" of genetic testing.
A new survey from Cegedim Relationship Management claims that digital tools are being underutilized and represent an opportunity to meet the demands of HCPs.
HCV drugs and other specialty medications drove a 13% increase in last year's prescription spending, the CBO overestimated just how much healthcare reform would cost, and an FDA panel voted 17-0 in favor of Kythera's drug that can reduce double chins.
Doctors tell MM&M that prescription weight-loss medications are just one component of an obesity treatment regimen.
The agency hopes the adoption of electronic informed consent measures could help participants retain and understand information as well as allow quicker timing of updates.
The open-source framework uses the iPhone's apps to gather users' health information.
Novartis CEO says cost cutting is looming; Novo Nordisk presents new Saxenda weight-loss data; FDA approves Astellas Pharma's antifungal drug.
The regulator approved Novartis's Neupogen lookalike. Amgen, which markets Neupogen, has a trove of its own potential biosimilars.
FDA approves the first biosimilar, judge rules that FDA panel members had conflicts of interest, and a new venture will evaluate the effectiveness of digital health technologies.
AbbVie's $21-billion bid to acquire Pharmacyclics may insulate the drugmaker from the impact of impending Humira biosimilars.
A study by the nonprofit research group found resistance to drug switching.
The move toward digital will likely bring greater collaboration between CMOs and CIOs.
The drugmakers will explore combinations of Merck's Keytruda and Eisai's Lenvima and Halaven to treat certain cancers.
AbbVie nabs Pharmacyclics for $21 billion, Mallinckrodt makes a Pfizer-Hospira style acquisition, and the National Cancer Institute's director resigns
The FDA granted the drug Priority Review status just last week.
Austin-based HCB Health announced Tuesday its acquisition of Chicago indie agency Topin & Associates in an effort to push the borders of its client base.
The drugmaker released interim clinical trial information in an SEC filing that the FDA wanted kept quiet until the trial was completed.
Haymarket purchased HCP-engagement specialist Group DCA and will operate the digital agency out of its custom medical communications division.
FDA adds new language to low-T drug labels; Afrezza's launch has a poor start, investors say; BMS acquires prostate-cancer vaccine in a deal worth $975 million.
The study indicates patients discount wording that indicates the FDA has not approved supplement claims.
The agreement includes a $1-million payment.
Holding company will now focus on two health networks—FCB Health and McCann Health
NICE greenlights Harvoni for Britain's national formulary, Pacira received a CRL instead of an expanded indication and Novo's latest diabetes outreach focuses on patients instead of drug brands.
Analysts say head-to-head study results could make Kyprolis the lead treatment.
Drugmakers face increasing pressure on pricing from insurers and PBMs.
The breakthrough designation therapy drug was the first for its drug class.
Researchers said 33% of Medicare Part D nursing home patients were receiving the drug for symptoms associated with dementia.
Boston Scientific buys Endo men's health business; Ranbaxy generic Nexium and Valcyte approvals denied by courts; BMS receives priority review for Opdivo lung-cancer indication.
Novartis heart failure drug's trial changed due to Alzheimer's disease concerns; Gilead appears to be stashing profits overseas; BMS releases high cure rate data for its investigational HCV combination.
The organization plans to publish a scientific and a lay abstract detailing study findings
Potential patients are expected to be newly diagnosed diabetes patients as opposed to Lantus switchers.
Some IDNs are centralizing decisionmaking at the corporate level and other hospitals are limiting on-site access to sales reps.
A report by the New York Times, citing a lack of an advisory committee for Vyvanse and illegal marketing lawsuits resolved last year, expressed concerns that the drug for binge-eating disorder will be overprescribed.
Industry rare disease awareness efforts included a pipeline overview at Pfizer as well as BI's efforts to draw attention to IPF.
The EU will have access to the new medication in May.
The survey shows the use of stronger-than-morphine painkillers has jumped.
Sanofi's Lantus predecessor nabs approval; Pharmacyclics reportedly vets acquisition offers; FDA biosimilar hearing is postponed.
Millennials and baby boomers have a lot of common: a desire for technology that supports health priorities.
Smartphones drove network traffic.
The over-the-counter weight-loss drug Alli saw a return to drugstores this week after a year hiatus.
Search queries for common diseases on the websites for the CDC and WebMD, among others, are being sent to third-party corporations.
J&J loses another Risperdal case; Pfizer slashes jobs at research center; Actavis challenges ulcerative colitis drug's patent.
Here's three items you need to know from our latest managed markets/payer feature: Formulary Fireworks
The global cancer market is expected to reach $111 billion by 2020, according to new market research, with immunotherapies—particularly in lung cancer—expected to drive growth.
Assemblyman David Chiu's bill would publish a drug's R&D and related costs.
Doctors want the National Health Service to allow them to prescribe the oncology drug for wet age-related macular degeneration.
Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.
- Lawmakers propose allowing pharma companies to share some off-label information
- US pharma market value projected to be $550 billion in five years
- Everyday Health buys rare-disease agency Cambridge BioMarketing
- Biosimilar uptake will require companies to tell a trustworthy backstory
- Apple's ResearchKit: Five Guidelines for Pharma